nach oben

Die Onkologie

Erschienen in:

01.08.2010 | Leitthema

Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom

Kommt die Individualisierung der Therapie?

verfasst von: PD Dr. T. Liersch, J. Gaedcke, M. Grade, T. Sprenger, L. Conradi, H. Becker, Prof. Dr. B.M. Ghadimi

Erschienen in: Die Onkologie | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aufgrund der Ergebnisse der CAO/ARO/AIO-94-Studie wird die 5-FU-basierte Langzeit-Radio-Chemo-Therapie (RCTx) zur Behandlung des lokal fortgeschrittenen Rektumkarzinoms (UICC-II-/III-Stadium) des unteren und mittleren Rektumdrittels (0–12 cm ab Anokutanlinie) empfohlen. Allerdings ist das Ansprechen des Tumors auf die RCTx sehr heterogen und reicht von der kompletten Remission bis zur Therapieresistenz. Unter der klinischen Forderung, eine an das „individuelle“ Rezidivrisiko angepasste multimodale Therapiestrategie zu entwickeln, sind in den vergangenen Jahren Fortschritte in der genomischen und proteomischen Analyse von zellulären Signaltransduktionswegen erzielt worden. Im Vergleich zu den postoperativ bestimmten klinikopathologischen Parametern für ein lokoregionales Ansprechen des Tumors auf die RCTx zeigte sich, dass ein so komplexer Phänotyp wie „Tumorresponse“ nicht vom Expressionslevel eines einzelnen oder mehrerer Gene und Proteine abhängt. Methoden wie die Microarray-Technologie eröffneten in den letzten Jahren die Möglichkeit, durch simultane Bestimmung der Expressionslevel von Zehntausenden von Genen die Komplexizität genetischer Signaltransduktionswege und ihre Vernetzung zu entschlüsseln. Unter Einsatz dieser Technologien lässt sich zukünftig unter studiengebundener Revalidierung der Responseparameter die angestrebte personalisierte genomische Medizin verwirklichen, in der Patienten auf der Basis der individuellen Tumorbiologie und des genetischen Profils onkologisch „maßgeschneidert“ behandelt werden.

Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61–70CrossRefPubMed

Ayers M, Symmans WF, Stec J et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284–2293CrossRefPubMed

Bengala C, Bettelli S, Bertolini F et al (2009) Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 20:469–474CrossRefPubMed

Bertagnolli M (2009) The forest and the trees: pathways and proteins as colorectal cancer biomarkers. J Clin Oncol 27:5866–5867 (Editorial)CrossRefPubMed

Bertolini F, Bengala C, Losi L et al (2007) Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68:1455–1461PubMed

Bonnefoi H, Potti A, Delorenzi M et al (2007) Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8:1071–1078CrossRefPubMed

Bosset JF, Collete L, Calais G et al (2006) Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123CrossRefPubMed

Bostner J, Ahnstrom WM, Fornander T et al (2007) Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26:6997–7005CrossRefPubMed

Bujko K, Glynne-Jones R, Bujko M (2010) Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomized trials. Ann Oncol (Epub ahead of print)

10.

Bujko K, Michalski W, Kepka L et al (2007) Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 67:369–377PubMed

11.

Capirci C, Valentini V, Cionini L et al (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 56 ypCR patients. Int J Rad Oncol Biol Phys 72:99–107

12.

Chan AK, Wong A, Jenken D et al (2005) Posttreatment TNM staging is aprognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61:665–677PubMed

13.

Chang JC, Wooten EC, Tsimelzon A et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362–369CrossRefPubMed

14.

Collette L, Bosset JF (2007) Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer. The type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients. In reply. J Clin Oncol 26:508–509CrossRef

15.

Collette L, Bosset JF, Dulk M den et al (2007) Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemtherapy? A trial of the European organisation for research and treatment of cancer radiation oncology group. J Clin Oncol 25:4379–4386CrossRefPubMed

16.

Croner RS, Förtsch T, Brückl WM et al (2008) Molecular signature for lymphatic metastasis in colorectal carcinomas. Ann Surg 247:803–810CrossRefPubMed

17.

De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508–515

18.

De Vries, Jong S de (2008) Eploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run. J Clin Oncol 26:5151–5153CrossRef

19.

Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712CrossRef

20.

Fang JY, Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6:322–327CrossRefPubMed

21.

Fernandez-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 Study. J Clin Oncol 28:859–865CrossRefPubMed

22.

Fietkau R, Barten M, Klautke G et al (2006) Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 49:1284–1292CrossRefPubMed

23.

Gaedcke J, Grade M, Jung K et al (2010) KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 94:76–81CrossRefPubMed

24.

Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625CrossRefPubMed

25.

Ghadimi BM, Grade M, Difilippantonio MJ et al (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826–1838CrossRefPubMed

26.

Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265–7277CrossRefPubMed

27.

Glimelius B, Oliveira J (2009) ESMO Guidelines Working Group. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (Suppl 4):54–56CrossRefPubMed

28.

Glynne-Jones R, Mawdsley S, Harrison M (2010) Cetuximab and chemoradiation for rectal cancer – is the water getting muddy? Acta Oncol 49(3):278–286CrossRefPubMed

29.

Grade M, Gaedcke J, Wangsa D et al (2009) Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. Cancer Genet Cytogenet 193(1):19–28CrossRefPubMed

30.

Grade M, Ghadimi BM, Varma S et al (2006) Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res 66:267–282CrossRefPubMed

31.

Grade M, Hörmann P, Becker S et al (2007) Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 67:41–56CrossRefPubMed

32.

Grade M, Hummon A, Camps J et al (2010) A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer (Epub ahead of print)

33.

Hannemann J, Oosterkamp HM, Bosch CA et al (2005) Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23:3331–3342CrossRefPubMed

34.

He Y, Van’t Veer LJ, Mikolajewska-Hanclich I et al (2009) PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 15:6956–6962CrossRefPubMed

35.

Hoshino R, Chatani Y, Yamori T et al (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813–822CrossRefPubMed

36.

Iwao-Koizumi K, Matoba R, Ueno N et al (2005) Prediction of docetaxel response in human reast cancer by gene expression profiling. J Clin Oncol 23:422–431CrossRefPubMed

37.

Jakob C, Aust DE, Meyer W et al (2004) Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 204:562–568CrossRefPubMed

38.

Jakob C, Liersch T, Meyer W et al (2005) Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol 29:1304–1309CrossRefPubMed

39.

Kappler M, Taubert H, Bartel F et al (2005) Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 13(1):167–172PubMed

40.

Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765CrossRefPubMed

41.

Kim IJ, Lim SB, Kang HC et al (2007) Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 50:1342–1353CrossRefPubMed

42.

Knutsen A, Adell G, Sun XF (2004) Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 60:149–155PubMed

43.

Kuremsky JG, Tepper JE, McLeod HL (2009) Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74:673–688PubMed

44.

Laurent-Puig P, Cayre A, Manceau G et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 5924–5930

45.

Liersch T, Grade M, Gaedcke J et al (2009) Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence. Cancer Genet Cytogenet 190:57–65CrossRefPubMed

46.

Liersch T, Langer C, Ghadimi BM et al (2006) Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 24:4062–4068CrossRefPubMed

47.

Lievre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379CrossRefPubMed

48.

Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995CrossRefPubMed

49.

Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338CrossRefPubMed

50.

Loupakis F, Ruzzo A, Cremolini C et al (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:715–721CrossRefPubMed

51.

Luna-Perez P, Segura J, Alvarado I et al (2000) Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 7:727–731CrossRefPubMed

52.

Mariadason JM, Arango D, Shi Q et al (2003) Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63:8791–8812PubMed

53.

McDowell DT, Smith FM, Reynolds JV et al (2009) Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. Int J Colorectal Dis 24:1261–1269CrossRefPubMed

54.

Negri FV, Campanini N, Camisa R et al (2008) Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 98:143–147CrossRefPubMed

55.

Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515–557CrossRefPubMed

56.

Okonkwo A, Musunuri S, Talamonti M et al (2001) Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep 8:497–500PubMed

57.

Potti A, Dressman HK, Bild A et al (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12:1294–1300CrossRefPubMed

58.

Quah HM, Chou JF, Gonen M et al (2008) Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 113:57–64CrossRefPubMed

59.

Rayala SK, Kumar R (2007) Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity. Biomed Pharmacother 61:408–411CrossRefPubMed

60.

Rectal cancer V.2. NCCN Clinical Practical Guidelines in Oncology 2010; http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf (cited 24 Feb 2010)

61.

Richman SD, Seymour MT, Chambers P et al (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931–5937CrossRefPubMed

62.

Rimkus C, Friederichs J, Boulesteix AL et al (2008) Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenerol Hepatol 6:53–61CrossRef

63.

Rödel C, Arnold D, Hipp M et al (2008) Phase I/II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70:1081–1086PubMed

64.

Rödel C, Grabenbauer GG, Papadoupolos T et al (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098–3104CrossRefPubMed

65.

Rödel C, Liersch T, Hermann RM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:100–117

66.

Rödel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression grading following preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696CrossRefPubMed

67.

Rödel F, Frey B, Leitmann W et al (2008) Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 71:247–255PubMed

68.

Rödel F, Hoffmann J, Distel L et al (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65:4881–4887CrossRefPubMed

69.

Rödel F, Hoffmann J, Grabenbauer GG et al (2002) High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178:426–435CrossRefPubMed

70.

Ross DT, Scherf U, Eisen MB et al (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227–235CrossRefPubMed

71.

Ryan BM, O’Donovan N, Duffy MJ et al (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35:553–562CrossRefPubMed

72.

Sauer R, Becker H, Hohenberger W et al (2004) Preoperative compared with postoperative chemoradiotherapy for locally advanced rectal cancer. N Engl J Med 351:1731–1740CrossRefPubMed

73.

Saw RP, Morgan M, Koorey D et al (2003) p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 46:192–202CrossRefPubMed

74.

Scherf U, Ross DT, Waltham M et al (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236–244CrossRefPubMed

75.

Schmiegel W, Reinacher-Schick A, Arnold D et al (2008) Update S3-Leitlinie „Kolorektales Karzinom“ 2008. Z Gastroenterol 46:799–784CrossRefPubMed

76.

Simon R (2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332–7341CrossRefPubMed

77.

Simon R (2009) Analysis of DNA microarray expression data. Best Pract Res Clin Haematol 22:271–282CrossRefPubMed

78.

Sprenger T, Rothe H, Jung K et al (2010) Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 8:27–37CrossRefPubMed

79.

Stauber RH, Mann W, Knauer SK (2007) Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67(13):5999–6002CrossRefPubMed

80.

Staunton JE, Slonim DK, Coller HA et al (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98:10787–10792CrossRefPubMed

81.

Terzi C, Canda AE, Sagol O et al (2008) Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis 23:37–45CrossRefPubMed

82.

Thuerigen O, Schneeweiss A, Toedt G et al (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24:1839–1845CrossRefPubMed

83.

Tolcher AW, Mita A, Lewis LD et al (2008) Phase I and pharmacokinetic study of 86YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26:5198–5203CrossRefPubMed

84.

Torres-Roca JF, Eschrich S, Zhao H et al (2005) Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 65:7169–7176CrossRefPubMed

85.

Valentini V, Aristei C, Glimelius B et al (2009) Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 92:148–163CrossRefPubMed

86.

Vijver MJ van de, He YD, Veer LJ van’t et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009CrossRefPubMed

87.

Veer LJ van’t, Dai H, Vijver MJ van de et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef

88.

Wang L, Cunningham JM, Winters JL et al (2003) BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 63:5209–5212PubMed

89.

Weiss C, Arnold D, Dellas K et al (2010) Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I–II trials. Int J Radiat Oncol Biol Phys (Epub ahead of print)

90.

Zauber NP, Marotta SP, Berman E et al (2009) Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. Int J Radiat Oncol Biol Phys 74:472–476PubMed

Titel: Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom
Kommt die Individualisierung der Therapie?
verfasst von: PD Dr. T. Liersch
J. Gaedcke
M. Grade
T. Sprenger
L. Conradi
H. Becker
Prof. Dr. B.M. Ghadimi
Publikationsdatum: 01.08.2010
Verlag: Springer-Verlag
Erschienen in: Die Onkologie / Ausgabe 8/2010
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-010-1866-y

Springer Medizin

Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom

Kommt die Individualisierung der Therapie?

Zusammenfassung

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2010

Rektumkarzinom

Die Pathologie in Therapiekontrolle und -planung beim Rektumkarzinom

Supportive Maßnahmen der Komplementärmedizin

Indikationen zur neoadjuvanten und adjuvanten Radio-Chemo-Therapie beim Rektumkarzinom

Sedierung am Lebensende

Brusterhaltung beim Mammakarzinom

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie